Lung cancer is one of the most common cancers, of which non-small cell lung cancer (NSCLC) accounts for approximately 85%.1 For patients with advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutations, EGFR tyrosine kinase inhibitor (EGFR-TKI) was the standard treatment and provided many treatment options. This evidence concerns the gene EGFR and lung carcinoma.